MedTrace Logo

Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

NCT01490983 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-08-13

No results posted yet for this study

Summary

This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.

Conditions

  • Chronic Myeloid Leukemia

Interventions

BEHAVIORAL

no access to eMedonline

patients will be followed for 3 months but will not use eMedonline

BEHAVIORAL

eMedonline access

patients will be given access to eMedonline use for 3 months

Sponsors & Collaborators

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Leap of Faith Technologies

    collaborator INDUSTRY

  • Rex Cancer Center, Raleigh, NC

    lead OTHER

Principal Investigators

  • Robert Wehbie, MD · Rex Cancer Center - Wakefield

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01490983 on ClinicalTrials.gov